La Lettre du Cancérologue • Vol. XVII - n° 8 - octobre 2008 | 385
DOSSIER THÉMATIQUE
1. Saslow D, Boetes C, Burke W et al. American Cancer
Society guidelines for breast screening with MRI as an adjunct
to mammography. CA Cancer J Clin 2007;57:75-89.
2. Kriege M, Brekelmans CI, Boetes C et al. Efficacy of
MRI and mammography for breast-cancer screening in
women with a familial or genetic predisposition. N Engl J
Med 2004;351(5):427-37.
3. Kuhl CK, Schrading S, Leutner C et al. Mammography,
breast ultrasound, and magnetic resonance imaging for
surveillance of women at high familial risk of breast cancer.
J Clin Oncol 2005;23(33):8469-76.
4. Leach MO, Boggis CR, Dixon AK et al.; MARIBS Study
group. Screening with magnetic resonance imaging and
mammography of a UK population at high familial risk
of breast cancer: a prospective multicentre cohort study
(MARIBS). Lancet 2005;365:1769-78.
5. Lehman CD, Blume JD, Weatherall P et al. Screening
women at high risk for breast cancer with mammography
and magnetic resonance imaging. Cancer 2005;103:
1898-905.
6. Warner E, Plewes DB, Hill KA et al. Surveillance of BRCA1
and BRCA2 mutation carriers with magnetic resonance
imaging, ultrasound, mammography, and clinical breast
examination. JAMA 2004;292:1317-25.
7. Hartmann LC, Schaid DJ, Woods JE et al. Efficacy of bilateral
prophylactic mastectomy in women with a family history of
breast cancer. N Engl J Med 1999;340(2):77-84.
8. Hartmann LC, Sellers TA, Schaid DJ et al. Efficacy of bila-
teral prophylactic mastectomy in BRCA1 and BRCA2 gene
mutation carriers. J Natl Cancer Inst 2001;93(21):1633-7.
9. Meijers-Heijboer H, van Geel B, van Putten WL et al.
Breast cancer after prophylactic bilateral mastectomy in
women with a BRCA1 or BRCA2 mutation. N Engl J Med
2001;345(3):159-64.
10. Rebbeck T, Friebel T, Lynch H et al. Bilateral prophylactic
mastectomy reduces breast cancer risk in BRCA1 and BRCA2
mutation carriers: the PROSE Study Group. J Clin Oncol
2004;22(6):1055-62.
11. Bermejo-Pérez MJ, Márquez-Calderón S, Llanos-
Méndes A. Effectiveness of preventive interventions in
BRCA1/2 gene mutation carriers: a systematic review. Int
J Cancer 2007;121:225-31.
12. Stefanek M, Helzlsouer KJ, Wilcox PM, Houn F. Predictors
of and satisfaction with bilateral prophylactic mastectomy.
Prev Med 1995;24:412-9.
13. Borgen PI, Hill AD, Tran KN et al. Patient regrets after
bilateral prophylactic mastectomy. Ann Surg Oncol
1998;5(7):603-6.
14. Frost MH, Schaid DJ, Sellers TA et al. Long-term satisfac-
tion and psychological and social function following bilateral
prophylactic mastectomy. JAMA 2000;284(3):319-24.
15. Hatcher MB, Fallowfield L, A’Hern R. The psychosocial
impact of bilateral prophylactic mastectomy: prospective
study using questionnaires and semistructured interviews.
BMJ 2001;322(7278):76.
16. Van Oostrom I, Meijers-Heijboer H, Lodder LN et al.
Long-term psychological impact of carrying a BRCA1/2
mutation and prophylactic surgery: a 5 year follow-up study.
J Clin Oncol 2003;21:3867-74.
17. Metcalfe KA, Esplen MJ, Goel V, Narod SA. Psychosocial
functioning in women who have undergone bilateral prophy-
lactic mastectomy. Psychooncology 2004;13:14-25.
18. Bresser PJ, Seynaeve C, Vangool AR et al. Satisfaction
with prophylactic mastectomy and breast reconstruction
in genetically predisposed women. Plast Reconstr Surg
2006;117:1675-82.
19. Pujol P, This P, Noruzinia M et al. Estrogens, anti-estro-
gens and familial breast cancer. Bull Cancer 2004;91(7-8):
583-91.
20. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen
for the prevention of breast cancer: current status of the
National Surgical Adjuvant Breast and Bowel Project
P1-study. J Natl Cancer Inst 2005;97:1652-62.
21. Cuzick J, Forbes JF, Sestak I et al. Long-term results
of tamoxifen prophylaxis for breast cancer–96 month
follow-up of the randomized IBIS-I trial. J Natl Cancer Inst
2007;99:272-82.
22. Powles T, Ashley S, Tidy A et al. Twenty-year follow-
up of the Royal Marsden randomized, double-blinded
tamoxifen breast cancer prevention trial. J Natl Cancer
Inst 2007;99:283-90.
23. Cuzick J, Powles T, Veronesi U et al. Overview of the
main outcomes in breast-cancer prevention trials. Lancet
2003;361(9354):296-300.
24. Vogel VG, Costantino JP, Wickerham DL et al. Effects of
tamoxifen vs raloxifene on the risk of developing invasive
breast cancer and other disease outcomes: the NSABP Study
of Tamoxifen and Raloxifen (STAR) P2 trial. JAMA 2006;
295:2727-41.
25. Kauff ND, Satagopan JM, Robson ME et al. Risk-reducing
salpingo-oophorectomy in women with a BRCA1 or BRCA2
mutation. N Engl J Med 2002;346(21):1609-15.
26. Rebbeck TR, Lynch HT, Neuhausen SL. Prophylactic
oophorectomy in carriers of BRCA1 or BRCA2 mutations.
N Engl J Med 2002;346:1616-22.
27. Finch A, Beiner M, Lubinski J et al. Salpingo-oophorec-
tomy and the risk of ovarian, fallopian tube, and peritoneal
cancers in women with a BRCA1 or BRCA2 Mutation. JAMA
2006;296(2):185-92.
28. Rebbeck TR, Friebel T, Wagner T et al. Effect of short-
term hormone replacement therapy on breast cancer risk
reduction after bilateral prophylactic oophorectomy in
BRCA1 and BRCA2 mutation carriers: the PROSE Study
Group. J Clin Oncol 2005;23(31):7804-10.
29. This P, Salmon R, Dolbeault S et al. Hormone replace-
ment therapy after prophylactic adnexectomy. Hereditary
Cancer in Clinical Practice 2005;3(4):181-2.
30. Eisinger F, Alby N, Bremond A et al. [INSERM-FNCLCC
collective expert’s report. Recommendations for manage-
ment of women having a genetic risk of developing breast
and/or ovarian cancer. National Federation of Centers of
the Fight Against Cancer]. Ann Endocrinol 1998;59(6):
470-84.
31. Eisinger F, Bressac B, Castaigne D et al. Identification
et prise en charge des prédispositions héréditaires aux
cancers du sein et de l’ovaire (mise à jour 2004). Bull Cancer
2004;91(3):219-37.
32. Kirova YM, Stoppa-Lyonnet D, Savignoni A et al. Risk of
breast cancer recurrence and contralateral breast cancer
in relation to BRCA1 and BRCA2 mutation status following
breast-conserving surgery and radiotherapy. Eur J Cancer
2005;41(15):2304-11.
33. Pierce LJ, Levin AM, Rebbeck TR et al. Ten-year multi-
institutional results of breast-conserving surgery and radio-
therapy in BRCA1/2-associated stage I/II breast cancer.
J Clin Oncol 2006;24(16):2437-43.
Références bibliographiques